Collaboration agreement ownership percentage in company.

No definition available.

Name:	psdv_CollaborationAgreementOwnershipPercentageInCompany
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Collaborative Agreements And Contracts [Line Items]

+ References

No definition available.

+ Details

Name:	psdv_CollaborativeAgreementsAndContractsLineItems
Namespace Prefix:	psdv_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Contingently recoverable accumulated commercialization losses.

+ References

No definition available.

+ Details

Name:	psdv_ContingentlyRecoverableAccumulatedCommercializationLosses
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

License Agreement Start Year Month

+ References

No definition available.

+ Details

Name:	psdv_LicenseAgreementStartYearMonth
Namespace Prefix:	psdv_
Data Type:	xbrli:gYearMonthItemType
Balance Type:	na
Period Type:	duration

- Definition

License Option Exercise Upfront Payment

+ References

No definition available.

+ Details

Name:	psdv_LicenseOptionExerciseUpfrontPayment
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum percentage of quarterly profit sharing offset by previously incurred and unapplied pre profitability net losses.

+ References

No definition available.

+ Details

Name:	psdv_MaximumPercentageOfQuarterlyProfitSharingOffsetByPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Milestone earned upon FDA approval.

+ References

No definition available.

+ Details

Name:	psdv_MilestoneEarnedUponFDAApproval
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Net Sales Threshold For Royalty Rate

+ References

No definition available.

+ Details

Name:	psdv_NetSalesThresholdForRoyaltyRate
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Non royalty consideration earned.

+ References

No definition available.

+ Details

Name:	psdv_NonRoyaltyConsiderationEarned
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Non royalty consideration percentage.

+ References

No definition available.

+ Details

Name:	psdv_NonRoyaltyConsiderationPercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Option period to acquire license.

+ References

No definition available.

+ Details

Name:	psdv_OptionPeriodToAcquireLicense
Namespace Prefix:	psdv_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Percentage of royalty offsetting.

+ References

No definition available.

+ Details

Name:	psdv_PercentageOfRoyaltyOffsetting
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Proceeds from earned profit share.

+ References

No definition available.

+ Details

Name:	psdv_ProceedsFromEarnedProfitShare
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Profit Sharing on Sale of Product Minimum Percentage After Maximum Allowable Offset of Previously Incurred and Unapplied Pre Profitability Net Losses.

+ References

No definition available.

+ Details

Name:	psdv_ProfitSharingOnSaleOfProductMinimumPercentageAfterMaximumAllowableOffsetOfPreviouslyIncurredAndUnappliedPreProfitabilityNetLosses
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Profit sharing on sale of product percentage.

+ References

No definition available.

+ Details

Name:	psdv_ProfitSharingOnSaleOfProductPercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Reduced contingently recoverable accumulated commercialization losses.

+ References

No definition available.

+ Details

Name:	psdv_ReducedContingentlyRecoverableAccumulatedCommercializationLosses
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Royalty percentage earned from sales of product

+ References

No definition available.

+ Details

Name:	psdv_RoyaltyPercentageEarnedFromProductSales
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Rate Percentage

+ References

No definition available.

+ Details

Name:	psdv_RoyaltyRatePercentage
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Share percentage of pre-profitability net losses on sale of product.

+ References

No definition available.

+ Details

Name:	psdv_SharePercentageOfPreProfitabilityNetLossesOnSaleOfProduct
Namespace Prefix:	psdv_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Upfront Cash Payment Received Under Collaboration Agreement

+ References

No definition available.

+ Details

Name:	psdv_UpfrontCashPaymentReceivedUnderCollaborationAgreement
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Upfront cash payment received under license agreement.

+ References

No definition available.

+ Details

Name:	psdv_UpfrontLicenseFeeReceived
Namespace Prefix:	psdv_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount, after allowance, receivable from customers, clients, or other third-parties, and receivables classified as other due within one year or the normal operating cycle, if longer.

+ References

No definition available.

+ Details

Name:	us-gaap_AccountsAndOtherReceivablesNetCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and maintenance revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Maintenance revenue is derived from maintenance services provided under contracts or arrangements with clients. Services may include the maintenance of software, plant and equipment, and facilities.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(d),(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_LicenseAndMaintenanceRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.

+ References

+ Details

Name:	us-gaap_LicenseAndServicesRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the value established as the selling price of the significant unit of accounting used to allocate the consideration of the multiple-deliverable arrangement.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 25
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68059916&loc=SL6750900-111635

+ Details

Name:	us-gaap_RevenueRecognitionMultipleDeliverableArrangementsDeterminationOfSellingPriceAmount
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

+ Details

Name:	us-gaap_RoyaltyRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_AlimeraSciencesIncMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_AlimeraSciencesIncAmendedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_PfizerCollaborationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_BauschAndLombMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_OncoSilMedicalUKLimitedMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=psdv_FeasibilityStudyAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

License and Collaboration Agreements - Additional Information (Detail) - USD ($)						1 Months Ended			3 Months Ended	12 Months Ended
	Jan. 01, 2021	Jan. 01, 2020	Jan. 01, 2019	Jul. 01, 2017	Oct. 25, 2016	Dec. 31, 2016	Mar. 31, 2013	Jun. 30, 2011	Dec. 31, 2016	Jun. 30, 2017	Jun. 30, 2016	Jun. 30, 2015	Mar. 31, 2017	Sep. 30, 2014
Collaborative Agreements And Contracts [Line Items]
Collaborative research and development revenue										$ 6,569,000	$ 398,000	$ 25,411,000
Royalty income										970,000	1,222,000	1,154,000
Accounts receivable										$ 251,000	488,000
Alimera [Member]
Collaborative Agreements And Contracts [Line Items]
Percentage of company's share of net profits										20.00%
Pre-profitability net losses percentage										20.00%
Maximum percentage offset of current period net profits against previously incurred and unapplied pre-profitability quarterly net losses										4.00%
Percentage of net profit share after offset of previously incurred and unapplied pre-profitability net losses										16.00%
Percentage of royalties received from sublicense										20.00%
Percentage of non-royalty consideration received from sublicense										33.00%
Collaborative research and development revenue										$ 659,000	233,000	25,100,000
Amount received, profit share from sale of licensed products										585,000
Non-royalty consideration received from sublicense											157,000
Milestone earned upon FDA approval of ILUVIEN														$ 25,000,000
Contingently recoverable accumulated commercialization losses										$ 25,000,000
Deferred revenue											136,000		$ 136,000
Amended Alimera [Member] \| Subsequent Event [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty percentage earned from sales of product				2.00%
Amended Alimera [Member] \| Scenario, Forecast [Member]
Collaborative Agreements And Contracts [Line Items]
Net sales threshold			$ 75,000,000
Reduced contingently recoverable accumulated commercialization losses		$ 5,000,000		$ 10,000,000
Royalty percentage offset applied to amounts earned above 2%	20.00%		50.00%
Amended Alimera [Member] \| Scenario, Forecast [Member] \| Minimum [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty percentage earned from sales of product			6.00%
Amended Alimera [Member] \| Scenario, Forecast [Member] \| Maximum [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty percentage earned from sales of product			8.00%
Pfizer Collaboration Agreement [Member]
Collaborative Agreements And Contracts [Line Items]
Collaborative research and development revenue									$ 5,600,000		0	0
Upfront cash payment received under collaboration agreement								$ 2,300,000
Estimated selling price of the deliverables for revenue recognition								$ 6,700,000
Option period to acquire license					60 days
License option upfront payment upon exercise					$ 10,000,000
Percentage of outstanding share capital owned by Pfizer										4.70%
Bausch and Lomb [Member]
Collaborative Agreements And Contracts [Line Items]
Royalty income										$ 970,000	1,200,000	1,200,000
Accounts receivable										$ 246,000	288,000
OncoSil Medical UK Limited [Member]
Collaborative Agreements And Contracts [Line Items]
Percentage of non-royalty consideration received from sublicense										20.00%
Collaborative research and development revenue										$ 100,000	100,000	100,000
Royalty percentage earned from sales of product										8.00%
License agreement commencement date										2012-12
Receipt of upfront license fee							$ 100,000
Payment of annual license maintenance fee						$ 100,000
Deferred revenue										$ 0
Feasibility Study Agreement [Member]
Collaborative Agreements And Contracts [Line Items]
Collaborative research and development revenue										$ 211,000	$ 33,000	$ 144,000